+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

I

Actively Recruiting

Chronic Obstructive Pulmonary Disease COPD is a major global health issue causing high morbidity and mortality, especially in low- and middle-income countries. The disease worsens with exacerbations, accelerating lung function decline and increasing death risk. Current guidelines recommend assessing lung function, exacerbation history, and symptoms to guide treatment, including triple therapy options like BreztriTrixeo BGF for patients with moderate to severe COPD who remain symptomatic despite dual therapy. The iCHOROS study aims to gather real-world data on BGFs impact on patient outcomes and quality of life in diverse populations across Latin America, Asia, and the Middle East & Africa. BGF is a fixed-dose inhaler combining budesonide ICS, glycopyrrolate LAMA, and formoterol fumarate LABA, delivered via Aerosphere technology. This observational study follows adults aged 30 to 80 who start BGF treatment as part of routine care, with no changes to standard medical management. Patients are followed for 52 weeks or until they stop BGF. Data are collected from medical records and scheduled visits at baseline, 12, 26, and 52 weeks, tracking clinical and patient-reported outcomes such as symptom scores, exacerbations, and inhaler satisfaction. Participants provide informed consent and complete questionnaires including the COPD Assessment Test CAT and modified Medical Research Council m-MRC dyspnea scale. Researchers monitor lung function tests and record exacerbation history and treatment patterns. The main goal is to assess changes in CAT scores after 12 weeks of BGF use, with additional measures at later visits. This study offers valuable insights into how BGF performs in everyday clinical settings, helping inform better COPD treatment decisions worldwide.

Age: 30Years - 80YearsAll Genders
36 locations